Safety Profile of Glycopyrronium Compared With Once-Daily Indacaterol in Patients With COPD With Moderate-to-Severe Airflow Limitation: The GEM3 Study

被引：0
|
作者：
Mahler, Donald
Gifford, Alex
Satti, Aditi
Jessop, Nicola
Eckert, Joerg H.
D'Andrea, Peter
Banerjee, Rudrani
机构：
[1] Geisel Sch Med Darmouth, Hanover, NH USA
[2] Temple Univ, Coll Med, Philadelphia, PA 19122 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
来源：
CHEST | 2015年 / 148卷 / 04期
关键词：
D O I：
10.1378/chest.2228025
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
734A
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
    Buhl, Roland
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 : 729 - 741
  • [2] Efficacy And Safety Of Glycopyrronium In COPD Patients With Moderate-To-Severe Airflow Limitation: The Gem1 Study
    LaForce, C.
    Pearle, J.
    Feldman, G.
    Spangenthal, S.
    Eckert, J. H.
    Mota, F.
    Henley, M.
    D'Andrea, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [3] Efficacy And Safety Of Indacaterol 75 G Once Daily In Patients With Moderate-To-Severe COPD
    Kerwin, E. M.
    Meli, J.
    Peckitt, C.
    Lassen, C.
    Kramer, B.
    Filcek, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [4] Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD (vol 7, pg 729, 2012)
    Buhl, R.
    Banerji, D.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2014, 9 : 287 - 287
  • [5] Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3)
    Mahler, Donald A.
    Gifford, Alex H.
    Satti, Aditi
    Jessop, Nicola
    Eckert, Joerg H.
    D'Andrea, Peter
    Mota, Fernando
    Banerjee, Rudrani
    RESPIRATORY MEDICINE, 2016, 115 : 39 - 45
  • [6] Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
    Salvi, Sundeep
    Kumar, Anand
    Agrawal, Sumit
    Leuva, Amrutlal
    Shukla, Vineet
    Deshpande, Shrikant
    Balamurugan, Santhalingum
    Singh, Ajeet
    Tikkiwal, Sharad
    Gupta, Sandeep
    Sawant, Sandesh
    Vaidya, Abhijit
    Gogtay, Jaideep
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [7] EFFICACY AND SAFETY OF ONCE-DAILY INDACATEROL/MOMETASONE COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE IN PATIENTS WITH MODERATE TO VERY SEVERE COPD
    Kirsten, Anne-Maria
    Richard, Alexia
    Tanase, Ana-Maria
    Cao Weihua
    Hosoe, Motoi
    Hederer, Bettina
    THORAX, 2014, 69 : A187 - A187
  • [8] Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study
    Decramer, Marc
    Wedzicha, Jadwiga A.
    Ficker, Joachim H.
    FowlerTaylor, Angel
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [9] Glycopyrronium Twice Daily Improves Lung Function And Health Status And Is Well Tolerated In COPD Patients With Moderate-To-Severe Airflow Limitation: The Gem2 Study
    Kerwin, E. M.
    Siler, T. M.
    Korenblat, P. E.
    White, A. C.
    Eckert, J. H.
    Cha, E.
    Mota, F.
    Andrea, P. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [10] Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
    Vincken, Walter
    Aumann, Joseph
    Chen, Hungta
    Henley, Michelle
    McBryan, Danny
    Goyal, Pankaj
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2014, 9 : 215 - 228
12345